阳普医疗(300030) - 2024 Q3 - 季度财报

Revenue and Profit Performance - Revenue for Q3 2024 was RMB 128.31 million, a decrease of 15.94% year-over-year[3] - Net profit attributable to shareholders for Q3 2024 was RMB -37.24 million, a decrease of 411.61% year-over-year[3] - Total revenue for the first nine months of 2024 was RMB 421.47 million, a decrease of 10.78% year-over-year[6] - Net profit attributable to shareholders for the first nine months of 2024 was RMB -42.52 million, a decrease of 1,434.95% year-over-year[6] - Total revenue for the quarter was 421,468,424.66 RMB, a decrease from 472,397,898.67 RMB in the same period last year[17] - Operating profit for the quarter was 384,110.58 RMB, significantly lower than the 4,527,871.16 RMB in the previous year[18] - Net profit attributable to the parent company's shareholders was -42,517,592.38 RMB, compared to 3,184,966.30 RMB in the same period last year[19] - The company's total comprehensive income was -44,614,651.60 RMB, compared to 5,549,263.65 RMB in the same period last year[19] - Basic earnings per share were -0.14 RMB, compared to 0.01 RMB in the same period last year[19] Revenue Breakdown by Product - Revenue from vacuum blood collection systems decreased by 6.05% year-over-year to RMB 266.55 million[6] - Revenue from reagents decreased by 9.23% year-over-year to RMB 59.05 million[6] - Revenue from software products and services decreased by 29.92% year-over-year to RMB 37.66 million[6] Investment and Fair Value Changes - Investment income decreased by 272.08% year-over-year to RMB -12.98 million due to reduced returns from Shenzhen Yanghe[7] - Fair value changes of investments resulted in a loss of RMB 35.18 million[7] - Net profit decreased by 904.12% to -44,632,335.57 yuan, primarily due to reduced investment income from Shenzhen Yanghe and changes in fair value of equity investments[8] - Operating profit dropped by 608.28% to -40,877,811.39 yuan, mainly due to decreased investment income from Shenzhen Yanghe and fair value changes[8] - Total profit fell by 628.83% to -41,339,058.29 yuan, driven by reduced investment income from Shenzhen Yanghe and fair value changes[8] Cash Flow and Tax-Related Activities - Cash received from tax refunds decreased by 68.81% to 5,591,786.14 yuan, due to reduced export tax rebates[9] - Cash received from other operating activities dropped by 71.29% to 10,001,877.28 yuan, due to reduced recovery of deposits and guarantees[9] - Cash paid for taxes decreased by 30.65% to 25,261,030.77 yuan, due to reduced VAT payments[9] - Cash received from disposal of fixed assets increased by 1113.73% to 36,510,988.39 yuan, due to partial recovery of land use rights and building payments from Chenzhou Development Zone[9] - Cash paid for construction of fixed assets increased by 125.92% to 49,311,322.27 yuan, due to increased payments for fixed assets[9] - Net cash flow from investment activities decreased by 584.73% to -11,840,244.58 yuan, due to reduced cash dividends from joint ventures[9] - Net cash flow from operating activities increased to RMB 42.79 million, up from RMB 34.44 million in the previous period[21] - Cash received from tax refunds was RMB 5.59 million, compared to RMB 17.93 million in the previous period[21] - Cash received from other operating activities was RMB 10.00 million, down from RMB 34.84 million in the previous period[21] - Total cash inflow from operating activities was RMB 502.79 million, compared to RMB 618.39 million in the previous period[21] - Cash paid for goods and services was RMB 230.16 million, down from RMB 264.81 million in the previous period[21] - Cash paid to employees was RMB 131.67 million, compared to RMB 147.75 million in the previous period[21] - Net cash flow from investing activities was negative RMB 11.84 million, compared to positive RMB 2.44 million in the previous period[21] - Net cash flow from financing activities was negative RMB 23.93 million, slightly improved from negative RMB 23.87 million in the previous period[21] - The ending cash and cash equivalents balance was RMB 219.22 million, compared to RMB 232.92 million in the previous period[22] Asset and Liability Changes - Total assets as of September 30, 2024, were RMB 1.33 billion, a decrease of 6.68% compared to the end of the previous year[3] - The company's monetary funds increased to 219.83 million yuan from 214.71 million yuan at the beginning of the period[15] - Trade receivables decreased to 162.38 million yuan from 184.10 million yuan at the beginning of the period[16] - Prepayments increased to 22.43 million yuan from 14.91 million yuan at the beginning of the period[16] - Other receivables decreased significantly to 7.61 million yuan from 44.77 million yuan at the beginning of the period[16] - Inventories increased slightly to 134.08 million yuan from 132.47 million yuan at the beginning of the period[16] - Total current assets decreased to 619.58 million yuan from 664.43 million yuan at the beginning of the period[16] - Total non-current assets decreased to 711.08 million yuan from 761.52 million yuan at the beginning of the period[16] - Total assets decreased to 1.33 billion yuan from 1.43 billion yuan at the beginning of the period[16] - Short-term borrowings decreased to 312.05 million yuan from 353.79 million yuan at the beginning of the period[16] - Trade payables decreased to 73.13 million yuan from 89.94 million yuan at the beginning of the period[16] - Total liabilities decreased to 613,063,403.45 RMB from 663,625,808.48 RMB in the previous year[17] - The company's total equity decreased to 717,595,629.38 RMB from 762,330,520.98 RMB in the previous year[17] - The company's total assets decreased to 1,330,659,032.83 RMB from 1,425,956,329.46 RMB in the previous year[17] Shareholder Information - The largest shareholder, Deng Guanhua, holds 15.91% of the shares, totaling 49,194,555 shares, with 36,895,916 shares pledged[10] Operating Costs and Expenses - The company's total operating costs were 413,928,591.21 RMB, a decrease from 477,874,723.34 RMB in the same period last year[17]